Variagenics to Report First Quarter Financial Results on May 1, 2001

Company to host conference call at 11:00 a.m.



Apr 24, 2001, 01:00 ET from Variagenics, Inc.

    CAMBRIDGE, Mass., Apr. 24 /PRNewswire Interactive News Release/ --
 Variagenics, Inc. (Nasdaq: VGNX), a leader in pharmacogenomics, the science
 that correlates genetic variation with drug response, today announced that the
 Company will report its First Quarter financial results on Tuesday, May 1,
 2001 at 7:30 a.m. and hold a conference call at 11:00 a.m. Eastern Time.
 Taylor J. Crouch, President and CEO, will lead the call.
 
      Date:                    Tuesday, May 1, 2001
      Time:                    11:00 a.m. Eastern Time
 
      Conference call numbers
      Toll-free:               (800) 946-0713
      Toll/international:      (719) 457-2642
      Webcast:                 www.variagenics.com
 
     There will be a replay (beginning at 2:00 p.m.) of the conference call for
 five days.  To replay the call, please dial (888) 203-1112 in the U.S. and
 (719) 457-0820, internationally.  The access code is 690212.
     Variagenics, inc. applies its pharmacogenomic technologies to the
 discovery, development and commercialization of individualized drugs and
 companion molecular diagnostic products. The Company identifies clinically
 important genetic variations, including SNPs and haplotypes (groups of SNPs),
 and uses this information to improve and enhance drugs in development and to
 identify and validate new drug targets. Variagenics is leveraging its
 technologies and expertise - including its new NuCleave(TM) genotyping and
 haplotyping analysis platform - into solutions for pharmaceutical companies
 and clinical laboratories seeking to optimize therapeutic outcomes for
 patients. For more information visit the Company's website at
 http://www.variagenics.com
     This press release may contain forward-looking statements.  Such
 statements are based on management's current expectations and are subject to
 certain factors, risks and uncertainties that may cause actual results, events
 and performance to differ materially from those referred to or implied in such
 statements.  These risks are identified in the Company's filings with the
 Securities and Exchange Commission, including but not limited to, the
 Company's Annual Report on Form 10-K for the year ended December 31, 2000. The
 Company does not intend to update any of the forward-looking statements after
 the date of this release to conform these statements to actual results or to
 changes in our expectations, except as required by law.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X92888029
 
 

SOURCE Variagenics, Inc.
    CAMBRIDGE, Mass., Apr. 24 /PRNewswire Interactive News Release/ --
 Variagenics, Inc. (Nasdaq: VGNX), a leader in pharmacogenomics, the science
 that correlates genetic variation with drug response, today announced that the
 Company will report its First Quarter financial results on Tuesday, May 1,
 2001 at 7:30 a.m. and hold a conference call at 11:00 a.m. Eastern Time.
 Taylor J. Crouch, President and CEO, will lead the call.
 
      Date:                    Tuesday, May 1, 2001
      Time:                    11:00 a.m. Eastern Time
 
      Conference call numbers
      Toll-free:               (800) 946-0713
      Toll/international:      (719) 457-2642
      Webcast:                 www.variagenics.com
 
     There will be a replay (beginning at 2:00 p.m.) of the conference call for
 five days.  To replay the call, please dial (888) 203-1112 in the U.S. and
 (719) 457-0820, internationally.  The access code is 690212.
     Variagenics, inc. applies its pharmacogenomic technologies to the
 discovery, development and commercialization of individualized drugs and
 companion molecular diagnostic products. The Company identifies clinically
 important genetic variations, including SNPs and haplotypes (groups of SNPs),
 and uses this information to improve and enhance drugs in development and to
 identify and validate new drug targets. Variagenics is leveraging its
 technologies and expertise - including its new NuCleave(TM) genotyping and
 haplotyping analysis platform - into solutions for pharmaceutical companies
 and clinical laboratories seeking to optimize therapeutic outcomes for
 patients. For more information visit the Company's website at
 http://www.variagenics.com
     This press release may contain forward-looking statements.  Such
 statements are based on management's current expectations and are subject to
 certain factors, risks and uncertainties that may cause actual results, events
 and performance to differ materially from those referred to or implied in such
 statements.  These risks are identified in the Company's filings with the
 Securities and Exchange Commission, including but not limited to, the
 Company's Annual Report on Form 10-K for the year ended December 31, 2000. The
 Company does not intend to update any of the forward-looking statements after
 the date of this release to conform these statements to actual results or to
 changes in our expectations, except as required by law.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X92888029
 
 SOURCE  Variagenics, Inc.